红日药业：公司目前的控制权结构稳定，公司治理规范

Core Viewpoint - The company, Hongri Pharmaceutical, asserts that its control structure is stable and governance is standardized, ensuring that strategic decisions are based on industry trends, resource alignment, and risk management, without deviation due to control changes [1] Group 1: Company Governance and Strategy - The company emphasizes that its research and development strategy is formulated and executed based on comprehensive considerations of industry trends, resource matching, and risk control [1] - There is no indication of strategic deviation or inaction due to changes in control [1] Group 2: Market and Financial Performance - The company's stock price fluctuations are influenced by macroeconomic factors, industry cycles, and market sentiment [1] - The company is actively working to enhance its value and market confidence through strengthening internal growth, advancing key projects, and improving investor communication [1] Group 3: Research and Development - The core pipeline of the company remains intact and is currently in a normal research and development phase [1] - Given the high investment, high risk, and long cycle characteristics of new drug development, substantial progress will be treated as significant information, and the company will disclose it through legal channels in a timely manner [1]